PhRMA urges USTR to address Japan's 'damaging' pricing policy, commends China's progress

PhRMA said the Office of the United States Trade Representative must prioritize action to end Japan's "damaging" pricing regulations. In its submission for USTR's upcoming annual Special 301 Report, PhRMA said USTR should add Japan to its list of "Priority Foreign Countries," a designation PhRMA said is reserved "for countries with the worst market access barriers and the most damaging intellectual property practices."